



"Replacement Sheet"




FIGURE 1.1 THE L929 CELL BASED ASSAY SHOWS THE GREATER NEUTRALIZATION ABILITY OF ANTI-TNF IgY AS COMPARED TO REMICADE. THE DOSE OF ANTIBODY WHICH PREVENTS 50 PERCENT OF THE CYTOTOXICITY ASSOCIATED WITH TNF (ND50) IS 70ng/ml FOR THE ANTI-TNF IgY, AND 140 ng/ml FOR REMICADE. NOTE: THE CONCENTRATIONS GRAPCHED FOR THE REMICADE ANTIBODY REPRESENT THE TOTAL AMOUNT OF SPECIFIC ANTIBODY, WHEREAS THE ANTI-TNF IgY CONCENTRATIONS REPRESENT TOTAL IgY CONCENTRATIONS, NOT SPECIFIC FOR TNF.

FIG. 1




FIGURE 2.1 THE HIGHEST ORAL DOSE OF ANTI-TNF PREVENTED TNBS-INDUCED ANIMAL WEIGHT LOSS AS COMPARED TO THE VEHICLE CONTROL AND LOWER DOSES (\*n=8, p<0.05 FOR ALL TIME POINTS). THE 7.5 mg/DAY DOSE WAS SIGNIFICANTLY HIGHER THAN THE VEHICLE AND 30mg/DAY DOSE AT DAYS 6 AND 10, AND ON DAY 7 HIGHER THAN THE VEHICLE GROUP (\*n=8, p<0.05). MANN-WHITNEY STATISTICAL TEST.

FIG. 2A




FIGURE 2.2 ORAL TREATMENT WITH ANTI-TNF REDUCED THE MEAN TOTAL COLON WEIGHT AT ALL DOSES MEASURED. THE 120mg/DAY DOSE IS STATISTICALLY SIGNIFICANT AS COMPARED TO THE VEHICLE AND LOWER DOSES (\*n=8, p<0.025, p<0.005, p<.01).  
MANN-WHITNEY STATISTICAL TEST

FIG. 2B

"Replacement Sheet"




FIGURE 2.3 ORAL TREATMENT WITH THE HIGHEST DOSE OF ANTI-TNF SIGNIFICANTLY REDUCED THE HISTOLOGICAL DAMAGE AS COMPARED TO THE VEHICLE AND TWO OTHER DOSES (\*n=8, p<.0025, p<0.005, p<.025). MANN-WHITNEY STATISTICAL TEST.

FIG. 2C




FIGURE 2.4 ORAL ADMINISTRATION OF 120 mg/DAY OF ANTI-TNF SIGNIFICANTLY REDUCES MPO LEVELS AS COMPARED TO THE VEHICLE CONTROL, AS WELL AS THE 7.5 mg/DAY AND 30 mg/DAY DOSES.  
(\*n=8, p<.0025, p<.005, and p<.005 RESPECTIVELY)  
MANN-WHITNEY STATISTICAL TEST.

FIG. 2D

"Replacement Sheet"




FIGURE 3.1 ORAL DELIVERY OF ANTI-TNF ANTIBODIES REDUCED COLONIC WEIGHT GAIN ASSOCIATED WITH TNBS TREATMENT. THE ANTI-TNF REDUCTION WAS STATISTICALLY SIGNIFICANT AS COMPARED TO THE PREIMMUNE TREATED CONTROL (\*n=8, p<0.001). MANN-WHITNEY STATISTICAL TEST.

FIG. 3A

"Replacement Sheet"      }




FIGURE 3.2 ORAL DELIVERY OF ANTI-TNF REDUCED HISTOLOGICAL DAMAGE FOR RATS TREATED WITH TNBS AS COMPARED TO VEHICLE (n=7, \*p<0.05) AND PREIMMUNE CONTROLS (N=8, \*p<0.001). NORMAL CONTROL WAS ZERO. MANN WHITNEY STATISTICAL TEST.

**FIG. 3B**

"Replacement Sheet"




FIGURE 3.3 TREATMENT WITH ANTI-TNF REDUCES HISTOLOGICAL DAMAGE AS COMPARED TO THE VEHICLE AND PREIMMUNE CONTROL ANIMALS (\*n=7, p<0.05, and p<0.0025 RESPECTIVELY). NORMAL CONTROL WAS ZERO. MANN-WHITNEY STATISTICAL TEST.

FIG. 3C

"Replacement Sheet"




FIGURE 3.4 ORAL DELIVERY OF ANTI-TNF ANTIBODIES SIGNIFICANTLY REDUCED THE LEVELS OF TISSUE MYSLOPEROXIDASE AFTER RAT TREATMENT WITH TNBS AS COMPARED TO THE PREIMMUNE (\*n=7, p<0.05). MANN-WHITNEY STATISTICAL TEST.

FIG. 3D

"Replacement Sheet"




FIGURE 4.1 ORAL ADMINISTRATION OF ANTI-TNF ANTIBODIES TO RATS 48 HOURS POST TREATMENT WITH TNBS SIGNIFICANTLY DECREASED DISEASE ASSOCIATED COLONIC WEIGHT GAIN AS COMPARED TO VEHICLE TREATED ANIMALS (\* $p<0.05$ ), SAW NO IMPROVEMENT OVER CONTROLS. MANN-WHITNEY STATISTICAL TEST.

FIG. 4A

"Replacement Sheet"




FIGURE 4.2 ORAL ADMINISTRATION OF ANTI-TNF ANTIBODIES TO RATS 48 HOURS POST TREATMENT WITH TNBS SIGNIFICANTLY DECREASED MORPHOLOGICAL DAMAGE AS COMPARED TO THE VEHICLE CONTROL (n=7, \*p<0.005). MANN-WHITNEY STATISTICAL TEST.

**FIG. 4B**

"Replacement Sheet"




FIGURE 4.3 TREATMENT WITH ANTI-TNF SIGNIFICANTLY REDUCES HISTOLOGICAL DAMAGE AS COMPARED TO THE SULFASALAZINE AND VEHICLE TREATED CONTROLS (\*n=7, p<0.01 AND p<0.001 RESPECTIVELY). MANN-WHITNEY STATISTICAL TEST.

FIG. 4C




FIGURE 4.4 ORAL ADMINISTRATION OF ANTI-TNF ANTIBODIES TO RATS 48 HOURS POST TNBS TREATMENT SIGNIFICANTLY REDUCED THE TISSUE MYLOPEROXIDASE AS COMPARED TO VEHICLE (n=7, \*p<0.002) AND SULFASALAZINE (n=7, \*p<0.02). MANN-WHITNEY STATISTICAL TEST.

FIG. 4D




FIGURE 5.1 ORAL ADMINISTRATION OF ANTI-TNF AND DEXAMETHASONE SIGNIFICANTLY REDUCE TOTAL COLON WEIGHT AS COMPARED TO THE VEHICLE CONTROL ( $n=9$ , \* $p<0.025$  AND  $p<0.05$  RESPECTIVELY). MANN-WHITNEY STATISTICAL TEST.

FIG. 5A

"Replacement Sheet"




FIGURE 5.2 ORAL ADMINISTRATION WITH ANTI-TNF SIGNIFICANTLY REDUCES MORPHOLOGICAL DAMAGE AS COMPARED TO THE VEHICLE AND DEXAMETHASONE TREATED GROUPS (\*n=9, p<0.05 AND p<0.025 RESPECTIVELY). MANN-WHITNEY STATISTICAL TEST.

FIG. 5B

"Replacement Sheet"




FIGURE 5.3 ORAL ADMINISTRATION WITH ANTI-TNF SIGNIFICANTLY REDUCES HISTOLOGICAL DAMAGE AS COMPARED TO THE DEXAMETHASONE AND VEHICLE TREATED ANIMALS (\*n=9, p<0.001 AND p<0.01). MANN-WHITNEY STATISTICAL TEST.

FIG. 5C

"Replacement Sheet"




FIGURE 5.4 ORAL ADMINISTRATION OF ANTI-TNF SIGNIFICANTLY REDUCES MYSLOPEROXIDASE LEVELS AS COMPARED TO DEXAMETHASONE TREATED ANIMALS (\*n=9, p<0.05). MANN-WHITNEY STATISTICAL TEST.

FIG. 5D

"Replacement Sheet"




FIGURE 6.1 ORAL TREATMENT WITH ANTI-TNF SIGNIFICANTLY DECREASES THE COLON WEIGHT AS COMPARED TO THE VEHICLE AND PREIMMUNE CONTROLS. (\* $p<0.025$  VS. VEHICLE AND PREIMMUNE). MANN-WHITNEY STATISTICAL TEST.

**FIG. 6A**

"Replacement Sheet"




FIGURE 6.2 ORAL TREATMENT WITH ANTI-TNF SIGNIFICANTLY DECREASES MORPHOLOGICAL DAMAGE AS COMPARED TO THE VEHICLE AND PREIMMUNE CONTROLS (\* $p<0.025$  VS. VEHICLE AND PREIMMUNE). MANN-WHITNEY STATISTICAL TEST.

FIG. 6B




FIGURE 6.3 ORAL TREATMENT WITH ANTI-TNF SIGNIFICANTLY DECREASES THE MICROSCOPIC DAMAGE AS COMPARED TO THE VEHICLE AND PREIMMUNE CONTROLS ( $p<0.025$  AND  $p<0.01$  RESPECTIVELY). MANN-WHITNEY STATISTICAL TEST.

FIG. 6C

"Replacement Sheet"




FIGURE 7.1 INTRARECTAL DELIVERY OF ANTI-TNF ANTIBODIES BEGINNING DAY 3 OF A 7 DAY DSS TREATMENT REGIMENT SIGNIFICANTLY REDUCES TISSUE MYELOPEROXIDASE LEVELS AS COMPARED TO PRE-IMMUNE CONTROL (n=5, \*p<0.05), BUT NOT THE VEHICLE CONTROL (n=10, \*p<0.2). MANN-WHITNEY STATISTICAL TEST.

FIG. 7

"Replacement Sheet"




FIGURE 8.1 INTRARECTAL DELIVERY WITH ANTI-TNF AFTER 5 DAYS OF DSS TREATMENT SIGNIFICANTLY REDUCED OCULT BLOOD FOUND IN THE STOOL OF DSS TREATED MICE AS COMPARED TO THE VEHICLE CONTROL. (\* $p<0.05$ ). CHI-SQUARED STATISTIC.

**FIG. 8A**

"Replacement Sheet"




FIGURE 8.2 INTRARECTAL TREATMENT WITH ANTI-TNF ANTIBODIES AFTER 5 DAYS OF DSS TREATMENT SIGNIFICANTLY REDUCED HISTOLOGICAL DAMAGE AS COMPARED TO VEHICLE CONTROL (\* $p<0.02$ ) AND PREIMMUNE CONTROLS (\* $p<0.001$ ). MANN-WHITNEY STATISTICAL TEST.

FIG. 8B

"Replacement Sheet"




FIGURE 8.3 INTRARECTAL DELIVERY OF ANTI-TNF ANTIBODIES AFTER 5 DAYS OF DSS TREATMENT DECREASED TISSUE MYELOPEROXIDASE LEVELS AS COMPARED TO THE VEHICLE CONTROL (\* $p<0.05$ ) AND THE PREIMMUNE CONTROL (\* $p<0.05$ ). MANN-WHITNEY STATISTICAL TEST.

FIG. 8C

"Replacement Sheet"




FIG. 9